Presentation is loading. Please wait.

Presentation is loading. Please wait.

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma  Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula.

Published byLaura Laakso Modified over 5 years ago

Similar presentations

Presentation on theme: "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma  Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula."— Presentation transcript:

1 The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma 
Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula Schilder, MD, Ingomar Naudts, MD, Anya Hammann-Haenni, PhD, Joerg Willers, PhD, Hans Stocker, PhD, Philipp Mueller, MD, Martin F. Bachmann, PhD, Wolfgang A. Renner, PhD  Journal of Allergy and Clinical Immunology  Volume 131, Issue 3, Pages (March 2013) DOI: /j.jaci Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 Outline of trial design and interventions performed. Prior to randomization, patients were converted to a run-in daily dosage of either 400 μg (for patients on μg BDP equivalent) or 800 μg of BDP (for patients on >800 μg BDP equivalent) inhaled morning and evening. The first 3 subcutaneous injections of study drug were given weekly and then every second week on opposite upper arms, alternatively. During the first 4 weeks, patients were maintained on 100% BDP. Then, the dose was reduced to 50% for the following 4 weeks. At the end of week 8, BDP was completely withdrawn for the last 4 weeks, if clinically justifiable and following predefined safety criteria (see this article's Online Repository at Site visits took place every 1 or 2 weeks. *Airway hyperresponsiveness was assessed at the time of maximum BDP reduction or at week 12. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig 2 CONSORT diagram. ITT, Intention to treat.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig 3 Change in ASMS and ACQ score and in FEV1 from baseline. A, Changes in ASMS given as delta scores between baseline and the respective visits. Absolute ASMS baseline and week 12 scores: Placebo 0.91 and 1.52; QbG and 1.01, respectively. B, Changes in reported scores on the 7-item-ACQ. Absolute baseline and week 12 scores: Placebo 0.92 and 1.48; QbG and 0.77, respectively. C, Changes in FEV1 of the 2 groups. Patients' morning FEV1 was measured always at the same time (±1 hour), and the best (highest) FEV1 per time point was documented. Absolute FEV1 baseline and week 12 scores: Placebo 2992 and 2741 mL; QbG and 3025 mL, respectively. P values (repeated measures) were calculated by using SAS Proc mixed. Error bars represent 95% confidence intervals. *P < .05 calculated for the mean difference between placebo and QbG10 at the respective week after randomization. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig 4 Change in average (asthma) symptom score (ASS) and average (asthma) medication score (AMS) from baseline. Changes in ASS (A) and AMS (B) determined with the patients' daily recordings in the asthma diaries are presented as delta scores between baseline and the respective visits. Both scores were calculated as the average between 2 visits. P values (repeated measures) were calculated by using SAS Proc mixed. Error bars represent 95% confidence intervals. *P < .05 calculated for the mean difference between placebo and QbG10 at the respective week after randomization. Absolute ASS baseline and week 12 scores: Placebo 0.91 and 1.18; QbG and 0.74, respectively. Absolute AMS baseline and week 12 scores: Placebo 0.91 and 1.86; QbG and 1.29, respectively. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

6 Fig 5 Percentage of patients with well-controlled asthma. The bars represent the percentage of patients with a 7-item-ACQ score of ≤0.75 points. P value (repeated measures) was calculated by using the Proc Genmod procedure. *P < .05 calculated for the mean difference between placebo and QbG10 at the respective week after randomization. Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci ) Copyright © 2013 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma  Kai-Michael Beeh, MD, Frank Kanniess, MD, Frank Wagner, MD, Cordula."

Similar presentations

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.

The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5- year follow-up: Effectiveness of early intervention with budesonide in.
Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 

Adherence with montelukast or fluticasone in a long-term clinical trial: Results from the Mild Asthma Montelukast Versus Inhaled Corticosteroid Trial 
Susan L. Limb, MD, Kathryn C. Brown, MD, Robert A. Wood, MD, Robert A

Susan L. Limb, MD, Kathryn C. Brown, MD, Robert A. Wood, MD, Robert A
A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,

A proof-of-concept study of the effect of a novel H3-receptor antagonist in allergen- induced nasal congestion  William T. Barchuk, MD, Anne Marie Salapatek,
Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M
F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 

F.Estelle R. Simons, MDa, Bruce M. Prenner, MDb, Albert Finn, MDc 
Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,

Treating acute rhinosinusitis: Comparing efficacy and safety of mometasone furoate nasal spray, amoxicillin, and placebo  Eli O. Meltzer, MD, Claus Bachert,
Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.

Oral Phenylephrine HCl for Nasal Congestion in Seasonal Allergic Rhinitis: A Randomized, Open-label, Placebo-controlled Study  Eli O. Meltzer, MD, Paul.
Alalia Berry, MD, William W. Busse, MD 

Alalia Berry, MD, William W. Busse, MD 
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma  Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,

Montelukast treatment may alter the early efficacy of immunotherapy in children with asthma  Paweł Majak, MD, PhD, Błażej Rychlik, PhD, Łukasz Pułaski,
Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,

Fluticasone furoate nasal spray: A single treatment option for the symptoms of seasonal allergic rhinitis  Harold B. Kaiser, MD, Robert M. Naclerio, MD,
Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,

Tiotropium improves lung function in patients with severe uncontrolled asthma: A randomized controlled trial  Huib A.M. Kerstjens, MD, PhD, Bernd Disse,
Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.

Effective treatment of house dust mite–induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled.
A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,

A phase III randomized controlled trial of tiotropium add-on therapy in children with severe symptomatic asthma  Stanley J. Szefler, MD, Kevin Murphy,
The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,

The Effect of Tiotropium in Symptomatic Asthma Despite Low- to Medium-Dose Inhaled Corticosteroids: A Randomized Controlled Trial  Pierluigi Paggiaro,
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?
A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.

A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow's milk allergy  Robert A.
Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Preventive effect of nasal filters on allergic rhinitis: A randomized, double-blind, placebo- controlled crossover park study  Peter Kenney, BSc, Ole Hilberg,

Similar presentations

Ads by Google